ONCAlert | Upfront Therapy for mRCC

Renal Cell Carcinoma VIEW MORE >>

In the CheckMate 025 trial, nivolumab remained superior to everolimus in terms of efficacy and safety in patients with advanced renal cell carcinoma at more than 5 years minimum follow-up and had continued responses in 28 percent of patients, according to a presentation at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.